Summary
Citations
Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002 Nov;20(4):365-74.[Abstract]
Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43.[Abstract][Full Text]
Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.[Abstract][Full Text]
1. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73.[Abstract][Full Text]
2. Serri O, Chik CL, Ur E, et al. Diagnosis and management of hyperprolactinemia. CMAJ. 2003 Sep 16;169(6):575-81.[Abstract][Full Text]
3. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002 Nov;20(4):365-74.[Abstract]
4. Josimovich JB, Lavenhar MA, Devanesan MM, et al. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril. 1987 May;47(5):785-91.[Abstract]
5. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008 Feb;29(1):1-41.[Abstract][Full Text]
6. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43.[Abstract][Full Text]
7. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998 Jun;19(3):225-68.[Abstract][Full Text]
8. Arowojolu AO, Akinloye O, Shittu OB. Serum and seminal plasma prolactin levels in male attenders of an infertility clinic in Ibadan. J Obstet Gynaecol. 2004 Apr;24(3):306-9.[Abstract]
9. Kanyicska B, Lerant A, Freeman ME. Endothelin is an autocrine regulator of prolactin secretion. Endocrinology. 1998 Dec;139(12):5164-73.[Abstract][Full Text]
10. Sarkar DK, Kim KH, Minami S. Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol. 1992 Nov;6(11):1825-33.[Abstract]
11. Shah GV, Pedchenko V, Stanley S, et al. Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. Endocrinology. 1996 May;137(5):1814-22.[Abstract]
12. Vilar L, Freitas MC, Naves LA, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008 May;31(5):436-44.[Abstract]
13. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab. 2007 Aug;92(8):2861-5.[Abstract][Full Text]
14. Bevan JS, Burke CW, Esiri MM, et al. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med. 1987 Jan;82(1):29-32.[Abstract]
15. Kasantikul V, Shuangshoti S. Pituitary adenomas: immunohistochemical: study of 90 cases. J Med Assoc Thai. 1990 Sep;73(9):514-21.[Abstract]
16. Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):408-12.[Abstract]
17. Beressi N, Beressi JP, Cohen R, et al. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris). 1999 Jun;150(4):327-41.[Abstract]
18. Bhardwaj M, Sharma A, Pal HK. Granulomatous hypophysitis. Neurol India. 2005 Sep;53(3):364-5.[Abstract][Full Text]
19. Cortet-Rudelli C, Sapin R, Bonneville JF, et al. Etiological diagnosis of hyperprolactinemia. Ann Endocrinol (Paris). 2007 Jun;68(2-3):98-105.[Abstract]
20. Goel P, Kahkasha, Narang S, et al. Evaluation of serum prolactin level in patients of subclinical and overt hypothyroidism. J Clin Diagn Res. 2015 Jan;9(1):BC15-7.[Abstract][Full Text]
21. Kyritsi EM, Dimitriadis GK, Angelousi A, et al. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome. Eur J Clin Invest. 2018 Jul;48(7):e12961.[Abstract]
22. Davoudi Z, Araghi F, Vahedi M, et al. Prolactin Level in Polycystic Ovary Syndrome (PCOS): an approach to the diagnosis and management. Acta Biomed. 2021 Nov 3;92(5):e2021291.[Abstract][Full Text]
23. Saha MT, Saha HH, Niskanen LK, et al. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002;92(3):735-7.[Abstract]
24. Pluguez-Turull CW, Nanyes JE, Quintero CJ, et al. Idiopathic granulomatous mastitis: manifestations at multimodality imaging and pitfalls. Radiographics. 2018 Mar-Apr;38(2):330-56.[Abstract]
25. Kallenberg GA, Pesce CM, Norman B, et al. Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA. 1990 May 9;263(18):2472-4.[Abstract]
26. Korytnaya E, Liu J, Camelo-Piragua S, et al. Ectopic prolactin secretion from a perivascular epithelioid cell tumor (PEComa). J Clin Endocrinol Metab. 2014 Nov;99(11):3960-4.[Abstract]
27. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314.[Abstract]
28. Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014 May;28(5):421-53.[Abstract][Full Text]
29. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005 Aug;80(8):1050-7.[Abstract][Full Text]
30. Teoh SK, Lex BW, Mendelson JH, et al. Hyperprolactinemia and macrocytosis in women with alcohol and polysubstance dependence. J Stud Alcohol. 1992 Mar;53(2):176-82.[Abstract]
31. Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs. 2010 Jul;24(7):563-74.[Abstract]
32. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics: a review. Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97.[Abstract]
33. Sarkar DK. Hyperprolactinemia following chronic alcohol administration. Front Horm Res. 2010;38:32-41.[Abstract]
34. Che Soh NAA, Yaacob NM, Omar J, et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2020 Nov 6;17(21):8199.[Abstract][Full Text]
35. Kasum M, Orešković S, Čehić E, et al. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol. 2017 Dec;56(6):719-24.[Abstract][Full Text]
36. De Schepper J, Schiettecatte J, Velkeniers B, et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol. 2003 Sep;149(3):201-7.[Abstract][Full Text]
37. Leanos A, Pascoe D, Fraga A, et al. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus. 1998;7(6):398-403.[Abstract]
38. Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002 Feb;87(2):581-8.[Abstract][Full Text]
39. Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018 Feb;39(1):3-16.[Abstract][Full Text]
40. Hattori N, Ishihara T, Ikekubo K, et al. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9.[Abstract]
41. Hattori N, Ikekubo K, Ishihara T, et al. Effects of anti-prolactin autoantibodies on serum prolactin measurements. Eur J Endocrinol. 1994 May;130(5):434-7.[Abstract]
42. Sachdev Y, Gopal K, Garg VK, et al. Pituitary apoplexy (spontaneous pituitary necrosis). Postgrad Med J. 1981 May;57(667):289-93.[Abstract][Full Text]
43. Serhal D, Weil RJ, Hamrahian AH. Evaluation and management of pituitary incidentalomas. Cleve Clin J Med. 2008 Nov;75(11):793-801.[Abstract]
44. Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):542-5.[Abstract][Full Text]
45. Maccagnan P, Macedo CL, Kayath MJ, et al. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab. 1995 Jul;80(7):2190-7.[Abstract]
46. Nawar RN, AbdelMannan D, Selman WR, et al. Pituitary tumor apoplexy: a review. J Intensive Care Med. 2008 Mar-Apr;23(2):75-90.[Abstract]
47. Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-23.[Abstract][Full Text]
48. Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.[Abstract][Full Text]
49. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023 Dec;19(12):722-740.[Abstract][Full Text]
50. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken, NJ: John Wiley & Sons Ltd; 2018.[Full Text]
51. Hammer F, Arlt W. Hypopituitarism [in German]. Internist (Berl). 2004 Jul;45(7):795-811.[Abstract]
52. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980 Dec 25;303(26):1511-4.[Abstract]
53. Biller BM. Hyperprolactinemia. Int J Fertil Womens Med. 1999 Mar-Apr;44(2):74-7.[Abstract]
54. Fideleff HL, Boquete HR, Sequera A, et al. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab. 2000 Mar;13(3):261-7.[Abstract]
55. Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70.[Abstract]
56. Arslan MS, Topaloglu O, Sahin M, et al. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract. 2014 May;20(5):447-51.[Abstract]
57. Wagner R, Heni M, Linder K, et al. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol. 2014 Feb;51(1):71-8.[Abstract]
58. Whyte MB, Pramodh S, Srikugan L, et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary. 2015 Jun;18(3):319-25.[Abstract]
59. Beda-Maluga K, Pisarek H, Komorowski J, et al. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation. J Physiol Pharmacol. 2014 Jun;65(3):359-64.[Abstract][Full Text]
60. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994 May 15;120(10):817-20.[Abstract]
61. Rand T, Kink E, Sator M, et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology. 1996 Nov;38(8):744-6.[Abstract]
62. Biller BM, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.[Abstract]
63. Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf). 2006 Oct;65(4):524-9.[Abstract]
64. Kawaguchi T, Ogawa Y, Tominaga T. Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging. BMC Res Notes. 2014 Aug 20;7:555.[Abstract][Full Text]
65. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-9.[Abstract][Full Text]
66. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999 Jul;51(1):119-26.[Abstract]
Key Articles
Referenced Articles
Sign in to access our clinical decision support tools